Also known as: Anti-PD-L1
Verastem (Research Partner)Merck KGaA (Research Partner)
Merck and Verastem partner to evaluate Verastem's defactinib (VS-6063) with Merck's avelumab in a Phase I/Ib trial to treat ovarian cancer
Merck KGaA (Licensor)Pfizer (Licensee)
Merck granted Pfizer rights to co-develop and co-commercialize Merck's MSB0010718C in combination with Pfizer's compounds, and Pfizer granted Merck rights to co-promote Xalkori in the U.S.
Set Email Alert